Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-06-13
1999-08-03
Davenport, Avis M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530313, 530328, A61K 3800, C07K 500, C07K 700
Patent
active
059325470
ABSTRACT:
This invention relates to stable non-aqueous polar aprotic formulations of peptide compounds. These stable formulations comprise peptide in non- aqueous polar aprotic solvent. They may be stored at elevated temperatures for long periods of time and are especially useful in implantable delivery devices for long term delivery of drug.
REFERENCES:
patent: 3914412 (1975-10-01), Gendrich et al.
patent: 4547370 (1985-10-01), Roeske
patent: 4661472 (1987-04-01), Rivier et al.
patent: 4689396 (1987-08-01), Roeske et al.
patent: 4851385 (1989-07-01), Roeske
patent: 5034229 (1991-07-01), Magruder et al.
patent: 5057318 (1991-10-01), Magruder et al.
patent: 5110596 (1992-05-01), Magruder et al.
patent: 5198533 (1993-03-01), Schally et al.
patent: 5480868 (1996-01-01), Kamei et al.
Fu Lu, et al., "Percutaneous Absorption Enhancement of Leuprolide", Pharmaceutical Research, 9/12, pp. 1575-1576 (1992).
Helm, et al., "Stability of Gonadorelin and Triptorelin in Aqueous Solution", Pharmaceutical Research, 7/12, pp. 1253-1256 (1990).
Johnson, et al., "Degradation of the LH-RH Analog Nafarelin Acetate in Aqueous Solution", Intl. J. of Pharmaceutics, 31, pp. 125-129 (1986).
Okada, et al., "Preparation of Three-Month Depot Injectable Microspheres of Leuprorelin Acetate Using Biodegradable Polymers", Pharmaceutical Research, 11/8, pp. 1143-1147 (1994).
Okada, et al., "New Degradation Product of Des-Gly.sup.10 -NH.sub.2 -LH-RH-Ethylamide (Fertirelin) in Aqueous Solution", J. of Pharmaceutical Sciences, 80/2, pp. 167-170 (1991).
Oyler, et al., "Characterization of the Solution Degradation Products of Histrelin, a Gonadotropin Releasing Hormone (LH/RH) Agonist", J. Pharmaceutical Sciences, 80/3, pp. 271-275 (1991).
Powell, et al., "Peptide Liquid Crystals: Inverse Correlation of Kinetic Formation and Thermodynamic Stability in Aqueous Solution", Pharmaceutical Research, 11/9, pp. 1352-1354 (1994).
Powell, et al., "Parenteral Peptide Formulations: Chemical and Physical Properties of Native Luteinizing Hormone-Releasing Hormone (LHRH) and Hydrophobic Analogues in Aqueous Solution", Pharmaceutical Research, 8/10, pp. 1258-1263 (1991).
Powers, et al., "Solution Behavior of Leuprolide Acetate, an LHRH Agonist, as Determined by Circular Dichroism Spectroscopy", Intl. J. of Pharmaceutics, 108, pp. 49-55 (1994).
Shi, et al., "Long-Term Stability of Aqueous Solutions of Luteinizing Hormone-Releasing Hormone Assessed by an In-Vitro Bioassay and Liquid Chromatography", J. of Pharmaceutical Sciences, 73/6, pp. 819-821 (1984).
Toguchi, "Pharmaceutical Manipulation of Leuprorelin Acetate to Improve Clinical Performance", J. of Intl. Medical Research, 18, pp. 35-41 (1990).
Factrel (gonadorelin HCI for subcutaneous of IV injection), Physician's Desk Reference, 50th Edition, pp. 2877-2878 (1996).
Lupron (leuprolide acetate for subcutaneous injection), Physician's Desk Reference, 50th Edition, pp. 2555-2556 (1996).
Lupron Depot (leuprolide acetate for depot suspension), Physician's Desk Reference, 50th Edition, pp. 2556-2562 (1996).
Lutrepulse (gonadorelin acetate for IV injection), Physician's Desk Reference, 50th Edition, pp. 980-982 (1996).
Zoladex (goserelin acetate implant), Physician's Desk Reference, 50th Edition, pp. 2858-2861 (1996).
Prestrelski Steven J.
Stevenson Cynthia L.
ALZA Corporation
Clarke Pauline Ann
Davenport Avis M.
Dillahunty Mary Ann
Stone Stephen F.
LandOfFree
Non-aqueous polar aprotic peptide formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-aqueous polar aprotic peptide formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-aqueous polar aprotic peptide formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-849468